文献速递临床试验与 GCP流行病学与生物统计

肯尼亚镰状细胞贫血幼童每月磺胺多辛/乙胺嘧啶-阿莫地喹或双氢青蒿素-哌喹疟疾化学预防:随机对照试验

Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2022-10-10

在肯尼亚疟疾低传播区开展的开放标签随机试验纳入246例1至10岁HbSS镰状细胞贫血患儿,按月随访12个月。与每日氯胍相比,每月磺胺多辛/乙胺嘧啶-阿莫地喹或双氢青蒿素-哌喹均未显著降低临床疟疾;双氢青蒿素-哌喹组指炎和恶性疟原虫感染率降低。

要点

  • 与每日氯胍相比,每月SP-AQ或DP未显著降低临床疟疾发生率。
  • 每月DP与指炎减少(IRR 0.47;95%CI 0.23–0.96;p=0.038)及恶性疟原虫感染减少(IRR 0.21;95%CI 0.08–0.56;p=0.002)相关。
  • SP-AQ组死亡7例 vs 氯胍组2例(HR 5.44;95%CI 0.92–32.11;p=0.064),差异未达统计学显著。

核心结论

  • 在疟疾传播有限的肯尼亚镰状细胞贫血患儿中,每月SP-AQ或DP未减少临床疟疾,但DP与指炎和恶性疟原虫感染减少相关。
  • 作者认为需在疟疾高传播地区开展化学预防的实用性研究。

研究设计与样本

  • 随机、开放标签试验,于2018年1月23日至2020年12月15日在肯尼亚Homa Bay开展。
  • 纳入246例1至10岁纯合血红蛋白S(HbSS)患儿,按1:1:1分配至每日氯胍组(n=81)、每月SP-AQ组(n=83)或每月DP组(n=82),按月随访12个月。
  • 主要分析人群为按实际治疗(As-Treated)人群;主要结局为12个月时临床疟疾的累积发病率。

主要发现

  • 总体53.3%(n=131)为男孩,平均年龄4.6±2.5岁;临床疟疾发病率为0.04次/人年。
  • 与每日氯胍组相比,每月SP-AQ组临床疟疾IRR为3.05(95%CI 0.36–26.14;p=0.39),每月DP组IRR为1.36(95%CI 0.21–8.85;p=0.90),均无显著差异。
  • 与每日氯胍组相比,每月DP组指炎发生率降低(IRR 0.47;95%CI 0.23–0.96;p=0.038);每月SP-AQ和DP组疼痛事件发生率无显著差异。
  • 与每日氯胍组相比,恶性疟原虫感染率在每月SP-AQ组相似(IRR 0.46;95%CI 0.17–1.20;p=0.13),在每月DP组降低(IRR 0.21;95%CI 0.08–0.56;p=0.002)。
  • 与每日氯胍组(n=2)相比,每月SP-AQ组死亡7例(HR 5.44;95%CI 0.92–32.11;p=0.064),每月DP组死亡1例(HR 0.61;95%CI 0.04–9.22;p=0.89),差异均未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究地点恶性疟原虫传播意外有限。
  • 羟基脲使用率高。
  • 试验参与者获得强化的支持治疗,可能限制向常规镰状细胞贫血诊疗更有限的高传播地区推广。
  • 作者认为需在疟疾高传播地区开展化学预防的实用性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention. Chemoprevention regimens vary between countries, and the comparative efficacy of prevention regimens is largely unknown. METHODS AND FINDINGS: We enrolled Kenyan children aged 1 to 10 years with homozygous hemoglobin S (HbSS) in a randomized, open-label trial conducted between January 23, 2018, and December 15, 2020, in Homa Bay, Kenya. Children were assigned 1:1:1 to daily Proguanil (the standard of care), monthly sulfadoxine/pyrimethamine-amodiaquine (SP-AQ), or monthly dihydroartemisinin-piperaquine (DP) and followed monthly for 12 months. The primary outcome was the cumulative incidence of clinical malaria at 12 months, and the main secondary outcome was the cumulative incidence of painful events by self-report. Secondary outcomes included other parasitologic, hematologic, and general events. Negative binomial models were used to estimate incidence rate ratios (IRRs) per patient-year (PPY) at risk relative to Proguanil. The primary analytic population was the As-Treated population. A total of 246 children were randomized to daily Proguanil (n = 81), monthly SP-AQ (n = 83), or monthly DP (n = 82). Overall, 53.3% (n = 131) were boys and the mean age was 4.6 ± 2.5 years. The clinical malaria incidence was 0.04 episodes/PPY; relative to the daily Proguanil group, incidence rates were not significantly different in the monthly SP-AQ (IRR: 3.05, 95% confidence interval [CI]: 0.36 to 26.14; p = 0.39) and DP (IRR: 1.36, 95% CI: 0.21 to 8.85; p = 0.90) groups. Among secondary outcomes, relative to the daily Proguanil group, the incidence of painful events was not significantly different in the monthly SP-AQ and DP groups, while monthly DP was associated with a reduced rate of dactylitis (IRR: 0.47; 95% CI: 0.23 to 0.96; p = 0.038). The incidence of Plasmodium falciparum infection relative to daily Proguanil was similar in the monthly SP-AQ group (IRR 0.46; 95% CI: 0.17 to 1.20; p = 0.13) but reduced with monthly DP (IRR 0.21; 95% CI: 0.08 to 0.56; p = 0.002). Serious adverse events were common and distributed between groups, although compared to daily Proguanil (n = 2), more children died receiving monthly SP-AQ (n = 7; hazard ratio [HR] 5.44; 95% CI: 0.92 to 32.11; p = 0.064) but not DP (n = 1; HR 0.61; 95% CI 0.04 to 9.22; p = 0.89), although differences did not reach statistical significance for either SP-AQ or DP. Study limitations include the unexpectedly limited transmission of P. falciparum in the study setting, the high use of hydroxyurea, and the enhanced supportive care for trial participants, which may limit generalizability to higher-transmission settings where routine sickle cell care is more limited. CONCLUSIONS: In this study with limited malaria transmission, malaria chemoprevention in Kenyan children with SCA with monthly SP-AQ or DP did not reduce clinical malaria, but DP was associated with reduced dactylitis and P. falciparum parasitization. Pragmatic studies of chemoprevention in higher malaria transmission settings are warranted. TRIAL REGISTRATION: clinicaltrials.gov (NCT03178643). Pan-African Clinical Trials Registry: PACTR201707002371165.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Taylor SM, Korwa S, Wu A, et al. Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. PLoS Med. 2022. PMID: 36215323. doi:10.1371/journal.pmed.1004104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。